Glucagon Market Size, Share & Trends Analysis Report By Product (Inject Glucagon, Nasal Glucagon.), By Applications (Emergency Use, General Use), By End Use, By Region, and Segment Forecasts - 2035

Glucagon Market Overview

glucagon market Size was estimated at 625.91 USD million in 2025, The industry is projected to grow from 664.09 USD million in 2026 to 793.18 USD million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.1% during the forecast period 2026 - 2035.

The Glucagon Market in 2026 is being shaped by stronger clinical emphasis on severe-hypoglycemia preparedness, broader prescribing for insulin-treated patients, preference for products that do not require reconstitution, and increasing demand for easier administration outside hospitals. Inject Glucagon is estimated to account for approximately 67% of Product Type demand, while Nasal Glucagon represents around 33%. Emergency Use dominates Applications with approximately 72% share, compared with about 28% for General Use. Current diabetes-care guidance defines level 2 hypoglycemia below 54 mg/dL and level 3 hypoglycemia as an event requiring assistance from another person, placing rescue therapy at the center of emergency planning. Modern treatment recommendations increasingly favor ready-to-use formulations because older injectable kits can require multiple preparation steps before administration. Glucagon products are now used across homes, schools, workplaces, hospitals, sports settings, and emergency-response environments, expanding the number of non-clinicians who may need to administer rescue medication. The market is therefore shifting from hospital-centered emergency treatment toward wider preparedness among patients, caregivers, family members, educators, and other support personnel.

The United States remains one of the most important Glucagon Markets because more than 38 million people live with diabetes, and millions use insulin or other therapies that can create clinically significant hypoglycemia risk. Emergency Use is estimated to represent approximately 75% of U.S. Application demand, reflecting prescribing for rescue from severe episodes rather than routine glucose management. Current clinical recommendations encourage glucagon prescriptions for all individuals taking insulin or otherwise considered at high risk for hypoglycemia. Inject Glucagon retains an estimated 63% U.S. Product Type share, while Nasal Glucagon accounts for approximately 37% as caregivers increasingly value needle-free administration. Available injectable emergency kits commonly contain 1 mg of glucagon, while nasal products are designed as single-dose systems requiring fewer preparation steps. U.S. adoption is also being supported by greater awareness among schools and caregivers because severe hypoglycemia can require immediate third-party intervention when a patient is unable to swallow carbohydrates safely.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Inject Glucagon is estimated to hold approximately 67% market share, supported by established hospital use, emergency kits, broad prescribing familiarity, and availability of 1 mg injectable formulations.
• Leading Application: Emergency Use is estimated to account for approximately 72% of demand because level 3 hypoglycemia requires assistance from another person and can necessitate immediate glucagon administration.
• Leading Region: North America is estimated to hold approximately 42% market share, supported by a U.S. diabetes population exceeding 38 million and extensive insulin-treated patient coverage.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 8.2% annually as diabetes prevalence, insulin use, emergency preparedness, and access to rescue therapies increase.
• Technology Trend: Ready-to-use delivery is gaining preference because modern rescue products can eliminate several reconstitution steps previously required before injectable glucagon administration.
• Market Driver: Clinical guidance increasingly supports glucagon prescribing for all insulin-treated individuals, widening the addressable population across millions of patients at hypoglycemia risk.
• Competitive Landscape: Supplier competition remains concentrated, with 3 supplied companies spanning injectable glucagon manufacturing, emergency kits, and established international diabetes-care distribution networks.
• Future Outlook: Nasal Glucagon is expected to gain share beyond the current approximately 33% as caregivers prioritize simple, needle-free rescue formats that can be administered rapidly.

Latest Trends

The most important trend in the Glucagon Market is the transition from multi-step rescue kits toward products that can be administered with minimal preparation. Traditional injectable glucagon can require the user to open a kit, combine diluent with lyophilized glucagon, mix the solution, draw the dose into a syringe, and administer it correctly during an emergency. Modern clinical recommendations increasingly prefer glucagon preparations that do not need reconstitution because severe hypoglycemia can impair consciousness and create substantial stress for caregivers. Nasal Glucagon benefits directly from this trend because the medication is delivered without injection and can reduce the number of handling steps from several actions to approximately 1 primary administration action once the device is prepared. Inject Glucagon nevertheless remains dominant at approximately 67% because hospitals, emergency departments, clinics, and established pharmacy channels continue using conventional 1 mg rescue formulations.

A second major trend is the expansion of glucagon preparedness beyond the patient. Current diabetes-care practices increasingly emphasize that family members, roommates, school personnel, coworkers, coaches, childcare professionals, and others providing support should know where glucagon is stored and how to administer it. This changes the market from one focused primarily on prescriptions to one involving education and accessibility. Emergency Use represents approximately 72% of total demand because glucagon is particularly important when a person cannot safely consume approximately 15 grams of fast-acting carbohydrate orally. Hospital hypoglycemia protocols also increasingly use standardized thresholds, including glucose below 70 mg/dL as hypoglycemia and below 54 mg/dL as clinically significant level 2 hypoglycemia. These thresholds encourage structured prevention, documentation, and rescue planning, strengthening demand for readily accessible glucagon across both institutional and community settings.

Market Dynamics

Driver

""Growing insulin use is strengthening demand for reliable severe-hypoglycemia rescue therapy.""

The principal driver of the Glucagon Market is the expanding number of people receiving insulin therapy and therefore exposed to hypoglycemia risk. More than 38 million people in the United States have diabetes, while hundreds of millions are affected globally. A significant proportion of people with type 1 diabetes and a substantial portion of those with type 2 diabetes require insulin. Current clinical recommendations state that glucagon should be prescribed for all individuals taking insulin or considered at high risk for hypoglycemia, creating a large potential user base. Emergency Use consequently represents approximately 72% of Application demand. A single severe episode can progress from confusion and impaired coordination to seizure or unconsciousness, making rescue therapy necessary when oral carbohydrates cannot be used safely.

Standardized hypoglycemia classification is also strengthening clinical awareness. Level 1 hypoglycemia is generally defined between 54 mg/dL and 69 mg/dL, level 2 occurs below 54 mg/dL, and level 3 is characterized by altered mental or physical functioning requiring external assistance. These 3 categories make it easier for clinicians and caregivers to identify patients who need rescue plans. Hospitals are also expected to maintain structured protocols when glucose falls below 70 mg/dL, reinforcing glucagon's role within institutional emergency care. As monitoring technology identifies more episodes and insulin therapy expands, physicians have more opportunities to prescribe rescue therapy proactively rather than only after a severe event has already occurred.

Restraint

""Low prescribing rates and access barriers continue to limit glucagon availability among eligible patients.""

A major restraint is that many individuals at risk of severe hypoglycemia still do not maintain an active glucagon prescription. Clinical recommendations repeatedly note that glucagon prescribing remains lower than desired despite guidance encouraging use among insulin-treated patients. If only a fraction of eligible users renew rescue medication before expiration, actual market penetration can remain substantially below theoretical demand. Traditional Inject Glucagon also presents usability challenges because multi-step reconstitution can be difficult during a stressful emergency. A caregiver unfamiliar with the process may need to complete 4-6 sequential actions before injection, increasing the possibility of hesitation or preparation errors.

Cost and insurance coverage also influence access. Health plans may cover only selected formulations, meaning patients can face different out-of-pocket requirements for Inject Glucagon and Nasal Glucagon. Rescue products also have defined shelf lives, requiring replacement even if they are never used. A patient who keeps glucagon at home, school, and work may need 2-3 separate units to ensure availability across locations, increasing total replacement requirements. These practical considerations can discourage stocking despite clinical recommendations. The market therefore depends not only on medical need but also on formulary coverage, education, pharmacy availability, renewal behavior, and caregiver confidence.

Opportunity

""Simplified delivery systems create significant opportunities to expand glucagon use outside clinical environments.""

The strongest opportunity lies in making glucagon easier for non-clinicians to administer. Nasal Glucagon currently represents approximately 33% of Product Type demand and directly addresses several limitations associated with traditional injection. Needle-free administration can be valuable in schools, homes, offices, sports settings, and travel environments where the person administering rescue medication may have no healthcare training. If Nasal Glucagon gains only 10 percentage points of market share through 2035, it would move from approximately 33% toward 43% of Product Type demand, materially changing competitive dynamics. Simplified delivery is especially relevant because level 3 hypoglycemia specifically requires another person's assistance.

Education programs provide another important opportunity. Current recommendations encourage patients and close contacts to know both the location of glucagon and how to use it. A household with 1 insulin-treated patient may involve 2-4 family members or caregivers who need basic rescue training. School-age patients can involve teachers, nurses, coaches, and childcare personnel, expanding the number of people who interact with each prescribed product. Manufacturers that provide simple instructions, demonstration devices, digital training, and clear emergency protocols can therefore increase correct utilization. Growth will increasingly depend on pairing medication availability with education rather than treating the product as an isolated prescription.

Challenge

""Emergency effectiveness depends on product availability, caregiver confidence, and correct administration.""

The main challenge is that glucagon is often administered during high-stress situations by someone other than the patient. The rescuer must recognize severe hypoglycemia, locate the product, understand the instructions, and administer it correctly. Traditional injection kits may require several preparation steps, while Nasal Glucagon simplifies the workflow but still depends on caregiver awareness. If glucagon is stored in an inaccessible location or has passed its expiration date, clinical availability does not translate into effective rescue. Emergency Use accounts for approximately 72% of demand, making real-world usability a central market requirement rather than a secondary product feature.

Preventive diabetes technologies also create a complex challenge. Continuous glucose monitoring systems can provide alerts before glucose becomes critically low, while automated insulin delivery systems can reduce some hypoglycemic events. Current guidance recommends automated insulin delivery for many insulin-treated patients, meaning the long-term market will evolve alongside prevention technology rather than independently. However, even advanced systems cannot eliminate all severe events because sensor failures, exercise, missed meals, dosing errors, illness, or unexpected physiological responses can still occur. Manufacturers must therefore position glucagon as a critical safety backup within an increasingly technology-enabled diabetes-management environment.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Inject Glucagon: Inject Glucagon leads with approximately 67% market share because injectable emergency kits have been used for decades across hospitals, clinics, homes, ambulances, and emergency-response environments. Commercial kits commonly provide approximately 1 mg glucagon per vial together with a syringe and diluent. Injectable glucagon is particularly important in professional clinical settings where staff are trained to prepare and administer medication rapidly. The segment also benefits from established manufacturing, procurement, pharmacy distribution, and treatment protocols. However, reconstitution requirements create disadvantages compared with ready-to-use formats, particularly when inexperienced caregivers must act during an emergency.

Nasal Glucagon: Nasal Glucagon represents approximately 33% market share and is one of the most important convenience-driven developments in hypoglycemia rescue. The format eliminates the needle and removes multiple solution-reconstitution steps associated with conventional injection kits. This makes administration more practical for family members, educators, coworkers, and other non-clinical caregivers. Nasal delivery is particularly relevant to Emergency Use, which represents approximately 72% of overall demand. The segment is projected to expand faster than Inject Glucagon through 2035 as clinical recommendations increasingly emphasize formulations that do not require reconstitution.

By Applications

Emergency Use: Emergency Use accounts for approximately 72% market share because glucagon is primarily required when severe hypoglycemia prevents normal oral carbohydrate treatment. Current clinical frameworks classify level 3 hypoglycemia as an event requiring assistance from another person. In hospitals, glucose below 70 mg/dL triggers treatment and monitoring, while values below 54 mg/dL indicate more clinically significant hypoglycemia. Emergency Use includes homes, hospitals, schools, ambulances, workplaces, sports settings, and community environments. Demand is supported by the need to keep rescue medication immediately available wherever high-risk patients spend substantial time.

General Use: General Use represents approximately 28% market share and includes broader preparedness, physician prescribing, patient education, institutional stocking, and selected diagnostic or clinical uses. The segment benefits from recommendations that glucagon should be prescribed proactively rather than only after a severe episode. A patient may maintain 2 or more rescue products across home, work, school, or travel locations even if actual administration is infrequent. General Use therefore supports recurring replacement demand through prescription renewals, expiration management, and changes in insurance coverage or preferred delivery format.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to lead the Glucagon Market with approximately 42% global share in 2026. The United States contributes the majority of regional demand because more than 38 million people live with diabetes and a substantial number receive insulin therapy. Emergency Use represents approximately 75% of regional Application demand, reflecting strong clinical emphasis on severe-hypoglycemia preparedness. Inject Glucagon accounts for approximately 63% of regional Product Type demand, while Nasal Glucagon contributes approximately 37%.

Regional adoption benefits from well-developed retail pharmacies, diabetes specialists, school-health programs, continuous glucose monitoring, insulin pumps, and emergency medical services. Clinical recommendations increasingly encourage glucagon prescriptions for all insulin-treated individuals or those otherwise at high risk. North America is projected to expand approximately 5-6% annually through 2035 as product convenience, caregiver training, and preventive prescribing improve. Needle-free delivery is expected to gain incremental share because it reduces multiple preparation steps during emergencies.

Europe

Europe represents approximately 29% of global Glucagon Market demand. Novo Nordisk provides strong supplied-company representation from Denmark, while Fresenius Kabi represents Germany. Emergency Use is estimated to account for approximately 70% of regional demand, while General Use contributes around 30%. Inject Glucagon remains dominant at approximately 69% because established hospital and pharmacy channels continue to support conventional rescue formulations.

European growth is supported by structured diabetes-management systems, broad insulin access, specialist endocrinology, and expanding adoption of continuous glucose monitoring. The region is projected to grow approximately 5-6% annually through 2035. Public healthcare procurement creates significant volume opportunities but can also increase price competition between established products. Training remains important because even in countries with mature healthcare systems, emergency glucagon may be administered by relatives or caregivers rather than healthcare professionals.

Asia-Pacific

Asia-Pacific is estimated to represent approximately 20% of global Glucagon Market demand and is projected to be the fastest-growing region at approximately 8.2% annually. China, Japan, India, South Korea, Australia, and Southeast Asian countries contain large and expanding diabetes populations. Emergency Use represents approximately 74% of regional demand as increasing insulin utilization creates greater need for rescue preparedness.

The region has significant long-term potential because diabetes prevalence is increasing while glucagon penetration remains uneven. Inject Glucagon is estimated to represent approximately 78% of regional Product Type demand because traditional injectable formats are more established and can be easier to introduce through hospital systems. Nasal Glucagon is expected to gain share as awareness and insurance coverage improve. Through 2035, regional expansion will depend on affordability, physician education, pharmacy availability, diabetes screening, and emergency-response training.

Middle East & Africa

Middle East & Africa represents approximately 4% of global Glucagon Market demand. Gulf states and selected urban African markets provide the strongest current adoption because diabetes treatment infrastructure and specialist care are more developed. Inject Glucagon is estimated to account for approximately 84% of regional Product Type demand, while Nasal Glucagon represents around 16%.

The region is projected to grow approximately 6-7% annually through 2035 as diabetes diagnosis, insulin treatment, and emergency medication access improve. Emergency Use represents approximately 78% of regional demand. The market nevertheless faces distribution, affordability, refrigeration-awareness, training, and prescription-access barriers in lower-income healthcare systems. Expansion will therefore rely on hospital procurement, diabetes-awareness programs, and distribution partnerships capable of reaching both public and private healthcare channels.

List of Top Glucagon Companies

• Novo Nordisk – Denmark
• Eli Lilly - United States
• Fresenius Kabi - Germany

Top 2 Companies Market Share

Eli Lilly: Eli Lilly is estimated to represent approximately 35-39% of competitive presence among the supplied companies, supported by longstanding diabetes expertise and strong positioning in simplified rescue therapy. Nasal Glucagon gives the company differentiated exposure to the approximately 33% needle-free Product Type segment, while Emergency Use represents approximately 72% of overall market demand. The company's established relationships with endocrinologists, pharmacies, diabetes educators, insurers, and patient-support programs provide broad access across the United States and international markets. Its competitive positioning is strengthened by clinical preference for products that reduce or eliminate reconstitution requirements.

Novo Nordisk: Novo Nordisk is estimated to account for approximately 31-35% of competitive presence among the supplied companies, supported by more than 100 years of experience in diabetes treatment and extensive global insulin distribution. Its presence across more than 80 international markets creates strong alignment with the large population at risk of insulin-related hypoglycemia. The company's position is concentrated more heavily in Inject Glucagon, which represents approximately 67% of Product Type demand. Novo Nordisk benefits from established diabetes-care infrastructure and longstanding relationships with specialists who manage patients requiring both insulin therapy and severe-hypoglycemia preparedness.

Investment Analysis

Investment in the Glucagon Market is increasingly focused on simplified administration, formulation stability, production reliability, caregiver education, and broader access. The most strategically important development is reducing the number of steps required during rescue. Traditional injection kits can involve approximately 4-6 actions before administration, while newer systems aim to reduce the process to approximately 1-2 actions. This difference is commercially significant because severe hypoglycemia can create confusion and urgency. Manufacturers are therefore investing in delivery platforms that require less training while maintaining long shelf life and stable dosing.

Access infrastructure represents another important investment area. Clinical recommendations potentially place millions of insulin-treated patients within the addressable glucagon population, but prescribing and renewal rates remain below full eligibility. Digital reminders, pharmacy education, school-health programs, physician decision support, and caregiver training can therefore expand real-world utilization. A patient keeping glucagon in 2 locations generates twice the stocking requirement of a patient maintaining only one device. Through 2035, strategic investment is expected to focus on approximately 5 areas: ready-to-use formulations, Nasal Glucagon, manufacturing capacity, patient access, and administration education.

New Product Development

New Product Development in the Glucagon Market is centered on reducing preparation complexity and improving usability under emergency conditions. Traditional lyophilized Inject Glucagon remains clinically important, but the market increasingly favors products that do not require mixing immediately before use. Nasal Glucagon demonstrates this direction by eliminating needles and several reconstitution steps. Product developers are also improving container design, dosing consistency, packaging visibility, instructions, and temperature stability. A rescue product may remain unused for 12 months or longer before replacement, making shelf-life performance and clear expiration management important features alongside pharmacological effectiveness.

Human-factor engineering is becoming equally important because glucagon is often administered by people without clinical training. Product developers increasingly evaluate whether caregivers can recognize the device, remove protective packaging, understand instructions, and deliver the full dose within approximately 1 minute. Training materials are being simplified around 3-5 core actions rather than complex technical language. Future products will compete across at least 6 attributes: administration speed, number of preparation steps, shelf life, portability, dosing reliability, and caregiver confidence. Nasal Glucagon is therefore expected to gain share, although injectable formulations will remain significant across hospitals and established emergency protocols.

Five Recent Developments

• December 2025: Updated 2026 diabetes-care recommendations reinforced glucagon prescribing for all individuals taking insulin or at high risk for hypoglycemia and continued preference for products not requiring reconstitution.
• November 2025: Fresenius Kabi maintained availability of a 1 mg Glucagon Emergency Kit together with additional 1 mg injectable glucagon presentations for institutional and emergency use.
• October 2025: Diabetes-care programs increasingly integrated glucagon education with continuous glucose monitoring and insulin-management workflows to strengthen severe-hypoglycemia preparedness across high-risk patients.
• June 2025: Ready-to-use and needle-free rescue formats continued gaining clinical preference as treatment protocols emphasized faster caregiver administration during level 3 hypoglycemia.
• January 2024: Clinical guidance continued shifting away from reconstitution-dependent rescue products where simpler formulations were available, reinforcing long-term demand for easier glucagon administration.

Report Coverage

The Glucagon Market report covers the 2026-2035 forecast period using the stated 2025 baseline and evaluates the supplied Product Types of Inject Glucagon and Nasal Glucagon. Estimated Product Type shares are approximately 67% and 33%, respectively. Application coverage includes Emergency Use at approximately 72% and General Use at around 28%. The analysis evaluates severe hypoglycemia preparedness, 1 mg injectable emergency kits, needle-free delivery, caregiver administration, diabetes-care recommendations, hospital protocols, pharmacy availability, prescription access, device usability, and patient education. Current clinical indicators include level 1 hypoglycemia between approximately 54 mg/dL and 69 mg/dL, level 2 below 54 mg/dL, and level 3 events requiring assistance from another person.

Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with estimated market shares of approximately 42%, 29%, 20%, 5%, and 4%, respectively. Competitive coverage includes all 3 supplied companies: Novo Nordisk, Eli Lilly, and Fresenius Kabi. The report evaluates how simplified rescue devices, broader insulin use, severe-hypoglycemia awareness, emergency preparedness, caregiver education, insurance coverage, and prescription practices will influence the market through 2035. Current market conditions favor products requiring fewer administration steps, while Inject Glucagon continues to represent approximately two-thirds of demand because of its established clinical use and global availability.